drugset / Trial / NCT05666310
Muscle Impact of Treating Osteoporosis
Phase 4
Active not recruiting
20 enrolled
Nami Safai Haeri
National Institute on Aging (NIA) · collabThe Claude D. Pepper Older Americans Independence Centers · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Osteosarcopenia is a geriatric musculoskeletal syndrome characterized by co-existence of osteoporosis and sarcopenia (low skeletal muscle mass, strength, and/or functional capacity). There is strong evidence of overlap between the pathophysiology of osteoporosis and sarcopenia (muscle-bone crosstalk). This research plan will further explore the relationship between bone and muscle, and provide new information about effect of osteoporosis medications on muscle health in older adults who are under treatment for osteoporosis.
Timeline
- Start
- 2023-02-14
- Primary completion
- 2026-01-05
- Completion
- 2026-09-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Denosumab | Monoclonal antibody | 60 mg | Subcutaneous |
| Comparator | Zoledronic acid | Other / unclassified | 5 mg | Intravenous |